LENZ Therapeutics (LENZ) Long-Term Deferred Tax (2022 - 2023)
LENZ Therapeutics (LENZ) reported Long-Term Deferred Tax of $73.0 for Q4 2023, down 100.0% year-over-year from $39.3 million in Q4 2022, and down 100.0% quarter-over-quarter from $39.3 million in Q4 2022.
LENZ Therapeutics (LENZ) Long-Term Deferred Tax (2022 - 2023) Analysis & Trends
LENZ Therapeutics (LENZ) has 2 years of Long-Term Deferred Tax data on file, last reported at $73.0 in Q4 2023.
- Long-Term Deferred Tax for Q4 2023 came in at $73.0, down 100.0% year-over-year; the trailing twelve-month figure through Dec 2023 was $73.0 (down 100.0% YoY), and the FY2023 annual result was $73.0, down 100.0% from the prior year.
- Long-Term Deferred Tax fell to $73.0 in Q4 2023 per LENZ's latest filing, from $39.3 million in the prior quarter.
- Over five years, Long-Term Deferred Tax peaked at $39.3 million in Q4 2022 and troughed at $73.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | LENZ Therapeutics | 192.19 Mn | 192.19 Mn | 825,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 73.00 |
| Dec 31, 2022 | 39.29 Mn |